Trustee Election
These are the original issues in this subcategory
  • BREAST CANCER
  • COLORECTAL CANCER
  • LUNG CANCER
Winning Issue » LUNG CANCER


Lung cancer is a disease characterized by uncontrolled cell growth in the tissues of the lung. If left untreated, this growth can spread to other parts of the body. Smoking tobacco is the most common cause of this disease, responsible for more than 80% of all lung cancer cases. Lung cancer accounts for 14% of all new cancers and is the second-most common cancer in men and women, behind prostate and breast cancers. Lung cancer is, by far, the leading cause of cancer death in America, outpacing breast, colon and prostate cancers combined. Nearly 230,000 new lung cancer cases are diagnosed each year and nearly 160,000 deaths annually result from this disease. About two-thirds of those diagnosed with lung cancer are 65 or older, with the average age at the time of diagnosis being about 70. It has been discovered that lung cancer can lie dormant for more than 20 years before turning deadly, helping explain why this disease is so persistent and difficult to treat. Recent studies show that after an initial disease-causing genetic fault, often due to smoking, tumor cells quietly develop numerous new mutations, making different parts of the same tumor genetically unique. The survival rates of people with lung cancer vary depending on the extent, or stage, of the cancer when it is diagnosed. There are now more than 380,000 American survivors of lung cancer, some of whom have used oral anti-cancer drugs which are now available. Oral cancer medications are convenient, less expensive to administer and effective if taken properly. However, our 2011 sequester cuts have impacted the availability of cancer medications to some patients. It is difficult for many cancer doctors, especially community oncologists who operate in nonhospital settings, to keep up with the costs associated with treating Medicare cancer patients who are typically elderly and on fixed incomes.

Fortunately, there is good news for those suffering from this disease. Cuban researches have recently developed a lung cancer vaccine called CimaVax which could soon be available here. CimaVax treats lung cancer's symptoms and could help prevent the disease from recurring in people who have gone a period of time without symptoms. It is thought that for some people, CimaVax could transform lung cancer from an immediate death sentence into a long term, semi-manageable disease like diabetes.


Pending Legislation:
H.R.1416 - Cancer Patient Protection Act of 2015
H.R.2739 - Cancer Drug Coverage Parity Act of 2015



Options


  • I oppose reforming current lung cancer policy and wish to defeat H.R.1416 - Cancer Patient Protection Act of 2015 and H.R.2739 - Cancer Drug Coverage Parity Act of 2015, and also wish to donate resources to the campaign committee of either Rep. Paul Ryan or Sen. Mitch McConnell
  • I support reducing the high cost of oral anticancer drugs by requiring individual health insurance plans to provide the same access to orally administered cancer drugs as they do to those that are administered intravenously, and wish to pass H.R.2739 - Cancer Drug Coverage Parity Act of 2015, and also wish to donate resources to either the campaign committees of Rep. Fred Upton (MI) and/or Rep. Leonard Lance (NJ), or to an advocate group currently working with this issue
  • I support repealing the sequestration as it pertains to the payment for cancer medications by declaring that the budgetary resources sequestered under that order for payments for drugs and biologicals under section 1847A of the Social Security Act (42 U.S.C. 1395w-4) shall be available for obligation for drugs and biologicals furnished on or after the date of the enactment of this Act in the same amount and manner as if such order had not been issued; directing the Secretary of Health and Human Services (HHS) to make any payments under Medicare part B of title XVIII of the Social Security Act as may be required to reimburse for reductions in payments made under the sequestration order for drugs and biologicals furnished on or after April 1, 2013, and before enactment of this Act, and wish to pass H.R.1416 - Cancer Patient Protection Act of 2015, and also wish to donate resources to either the campaign committees of Rep. Tom Price (GA) and/or Rep. Renee Ellmers (NC), or to an advocate group currently working with this issue


Winning Option
  • I support reducing the high cost of oral anticancer drugs by requiring individual health insurance plans to provide the same access to orally administered cancer drugs as they do to those that are administered intravenously, and wish to pass H.R.2739 - Cancer Drug Coverage Parity Act of 2015, and also wish to donate resources to either the campaign committees of Rep. Fred Upton (MI) and/or Rep. Leonard Lance (NJ), or to an advocate group currently working with this issue
There has been $0.00 pledged in support of this issue
Trustee Candidates

If elected as a trustee, the campaign committee of Rep. Fred Upton (MI) will be unconditionally awarded the funds pledged to this issue along with a letter requesting him to favorably consider passing H.R.2739 - Cancer Drug Coverage Parity Act of 2015. If more than $1,000 has been pledged, the campaign committee of sponsor Rep. Leonard Lance (NJ) will be unconditionally awarded 10% of these funds.

Legislation: H.R.2739 - Cancer Drug Coverage Parity Act of 2015
Sponsor: Rep. Leonard Lance, NJ
Status: House Energy and Commerce Committee
Chairman: Rep. Fred Upton, MI

If elected as a trustee, NLCP will be awarded the funds pledged to this issue along with a letter requesting these funds be used to expand its efforts to prevent, treat and cure lung cancer.

The mission of the National Lung Cancer Partnership (NLCP) is to decrease deaths due to lung cancer and to help patients live longer and better through research, awareness and advocacy. Its vision is to fund research with the greatest potential to save lives, help all patients fully understand their treatment options, ensure molecular tumor testing is standard of care and double the number of lung cancer patients participating in clinical trials. The National Lung Cancer Partnership is the only lung cancer advocacy organization founded by doctors and researchers working together with survivors and advocates to increase lung cancer awareness and research funding. Headquartered in Madison, WI, the Partnership supports a nationwide network of grassroots lung cancer advocates through its programs. The Partnership has official state chapters in Florida, Louisiana and Pennsylvania. Since 2005, the Partnership has awarded more than $3.7 million for cutting-edge research that is essential to helping patients live longer and better lives.
I wish to select my own choice of trustee from the following list of legislators:

To participate in the Trustee Election you must first pledge support to this issue.
Click here if you wish to make a pledge.
Trustee Election - Opening Date
February 27, 2020
Trustee Election - Closing Date
March 4, 2020